ADC Therapeutics SA (NYSE:ADCT) stock is continuing its downward trajectory on Friday, following an intense market reaction to newly released clinical data.
The ongoing slide hits retail traders on the heels of a massive selloff that began during Thursday’s session, where the stock collapsed 49.68%. Investors continue to digest structural safety issues found in the biotech company’s latest study.
Something went wrong.
Mixed Trial Results Yield Fatal Safety Signals
The stock underperformance stems directly from the topline results of the Phase 3 LOTIS-5 confirmatory trial. The study evaluated ZYNLONTA in combination with rituximab for patients suffering from relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
